Organization | Pipeline Therapeutics, Inc.

Pipeline Therapeutics, Inc. Report issue

For profit Phase 1 Phase 2

Founded: San Diego CA United States (2017)

Organization Overview

First Clinical Trial

2020

NCT04462198

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Alternative names

Chief Medical Officer, Pipeline Therapeutics, Inc | Chief Medical Officer, Pipeline Therapeutics, Inc. | Pipeline Therapeutics, Inc. | Stemline Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (10)

abemaciclib (verzenio) (1 trial)

alpelisib (Piqray) (1 trial)

azacitidine (vidaza) (2 trials)

elacestrant (Orserdu) (4 trials)

everolimus (zortress) (1 trial)

palbociclib (ibrance) (1 trial)

pipe-307 (3 trials)

pipe-505 (1 trial)

ribociclib (kisqali) (1 trial)

tagraxofusp-erzs (elzonris) (2 trials)

Drugs in Phase 1 Trials (2)

pipe-791 (1 trial)

sl-901 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Deafness (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 12
# of Trial APIs: 12